Atyr Pharma Inc [NASDAQ: ATYR] slipped around -0.06 points on Friday, while shares priced at $0.99 at the close of the session, down -5.51%.
Compared to the average trading volume of 8.70M shares, ATYR reached a trading volume of 26808511 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Atyr Pharma Inc [ATYR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATYR shares is $8.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATYR stock is a recommendation set at 2.45. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Atyr Pharma Inc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on September 16, 2025. The new note on the price target was released on September 15, 2025, representing the official price target for Atyr Pharma Inc stock. Previously, the target price had yet another raise to $1, while Leerink Partners analysts kept a Market Perform rating on ATYR stock.
The Price to Book ratio for the last quarter was 1.23, with the Price to Cash per share for the same quarter was set at 0.82.
How has ATYR stock performed recently?
Atyr Pharma Inc [ATYR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -83.55. With this latest performance, ATYR shares dropped by -79.84% in over the last four-week period, additionally sinking by -73.61% over the last 6 months – not to mention a drop of -72.59% in the past year of trading.
Atyr Pharma Inc (ATYR) Capital Structure & Debt Analysis
According to recent financial data for Atyr Pharma Inc. ( ATYR), the Return on Equity (ROE) stands at -85.18%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -64.24%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Atyr Pharma Inc’s Return on Invested Capital (ROIC) is -77.31%, showcasing its effectiveness in deploying capital for earnings.
Atyr Pharma Inc (ATYR) Efficiency & Liquidity Metrics
Based on Atyr Pharma Inc’s (ATYR) latest financial statements, the Debt-to-Equity Ratio is 0.17%, indicating its reliance on debt financing relative to shareholder equity.
Atyr Pharma Inc (ATYR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Atyr Pharma Inc. (ATYR) effectively leverages its workforce, generating an average of -$1129491.53 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.63% and a Quick Ratio of 5.63%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Atyr Pharma Inc [ATYR]
With the latest financial reports released by the company, Atyr Pharma Inc posted -0.23/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATYR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Atyr Pharma Inc go to 12.08%.
Insider trade positions for Atyr Pharma Inc [ATYR]
There are presently around $68.71%, or 70.13%% of ATYR stock, in the hands of institutional investors.
